Pacira BioSciences (NASDAQ:PCRX) Trading Up 2.7%

Pacira BioSciences, Inc. (NASDAQ:PCRX) shares were up 2.7% during trading on Tuesday . The stock traded as high as $27.32 and last traded at $27.24. Approximately 113,521 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 489,085 shares. The stock had previously closed at $26.53.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on PCRX shares. TheStreet raised Pacira BioSciences from a “d+” rating to a “c” rating in a report on Thursday, February 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, April 9th. Wedbush reaffirmed an “outperform” rating and issued a $57.00 price objective on shares of Pacira BioSciences in a research note on Thursday, February 8th. JPMorgan Chase & Co. initiated coverage on Pacira BioSciences in a research report on Thursday, March 7th. They set an “overweight” rating and a $45.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Pacira BioSciences in a research report on Monday, March 4th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Pacira BioSciences presently has an average rating of “Buy” and a consensus target price of $49.50.

Pacira BioSciences Trading Down 0.4 %

The business has a fifty day moving average price of $29.12 and a 200 day moving average price of $29.82. The company has a market capitalization of $1.24 billion, a PE ratio of 33.05 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, February 29th. The company reported $0.71 EPS for the quarter, hitting analysts’ consensus estimates of $0.71. The company had revenue of $181.24 million for the quarter, compared to the consensus estimate of $180.60 million. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. Analysts expect that Pacira BioSciences, Inc. will post 2.18 EPS for the current fiscal year.

Insider Activity at Pacira BioSciences

In other Pacira BioSciences news, Director Gary W. Pace sold 1,066 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the sale, the director now owns 140,384 shares in the company, valued at approximately $4,165,193.28. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director Gary W. Pace sold 90,000 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the transaction, the director now owns 22,127 shares in the company, valued at approximately $677,086.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gary W. Pace sold 1,066 shares of Pacira BioSciences stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total value of $31,628.22. Following the sale, the director now directly owns 140,384 shares in the company, valued at approximately $4,165,193.28. The disclosure for this sale can be found here. Company insiders own 6.60% of the company’s stock.

Institutional Trading of Pacira BioSciences

Hedge funds have recently added to or reduced their stakes in the business. ICA Group Wealth Management LLC bought a new stake in shares of Pacira BioSciences in the 4th quarter worth $30,000. Financial Freedom LLC bought a new stake in shares of Pacira BioSciences in the 4th quarter worth $33,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Pacira BioSciences by 96.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company’s stock worth $36,000 after acquiring an additional 583 shares during the last quarter. Neo Ivy Capital Management acquired a new position in shares of Pacira BioSciences in the 2nd quarter worth $44,000. Finally, Torno Capital LLC acquired a new position in shares of Pacira BioSciences in the 4th quarter worth $51,000. Institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.